Follicle Stimulating Hormone Market Report 2026

Follicle Stimulating Hormone Market Overview

• Follicle Stimulating Hormone market size has reached to $2.12 billion in 2025 • Expected to grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: Follicle-Stimulating Hormone Market Surges With The Rising Adoption Of assisted reproductive technology • Market Trend: Breakthrough In The Follicle-Stimulating Hormone Market For Enhanced infertility treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Follicle Stimulating Hormone Market?

Follicle-stimulating hormone is a hormone that the pituitary gland secretes and is involved in sexual maturation and reproduction. It has an impact on how well the testicles and ovaries work. Follicle-stimulating hormone assists in regulating both the ovaries' egg production and the menstrual cycle. The main types of follicles stimulating hormones are recombinant FSH and urinary FSH. Recombinant FSH (Follicle-Stimulating Hormone) is a type of FSH that is synthesized using recombinant DNA technology instead of being sourced from natural sources like urine. These are used for several applications, including infertility treatment, assisted reproductive technology (ART), and others, which are used by various end-users, such as infertility centers, hospitals, and others.

What Is The Follicle Stimulating Hormone Market Growth Forecast?

The follicle stimulating hormone market size is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to technological innovations in fsh delivery systems, growth of assisted reproductive technology (art) centers, expansion of telehealth for fertility care, government support for infertility treatments, increasing demand for personalized medicine in reproductive health. Major trends in the forecast period include personalized fertility treatments, increased use of recombinant hormones, integration of telemedicine in fertility care, focus on female reproductive health awareness, expansion of assisted reproductive technology (art) clinics.

Global Follicle Stimulating Hormone Market Segmentation

1) By Type: Recombinant FSH, Urinary FSH 2) By Application: Infertility Treatment, Assisted Reproductive Technology (ART), Other Applications 3) By End-Users: Infertility Center, Hospitals, Other End-Users Subsegments: 1) By Recombinant FSH: Pure Recombinant FSH, Mixed Recombinant FSH Formulations 2) By Urinary FSH: Purified Urinary FSH, Urinary FSH Combined With Other Hormones

What Is The Driver Of The Follicle Stimulating Hormone Market?

The increasing adoption of assisted reproductive technology is expected to propel the growth of the follicle-stimulating hormone market in the coming years. Assisted Reproductive Technology (ART) is a term for medical procedures or practices that help people or couples conceive when traditional means have failed. The use of follicle-stimulating hormone in assisted reproductive technology is a well-established therapy that tries to improve the odds of a successful pregnancy for people or couples who are experiencing reproductive issues. For instance, in March 2024, according to the US department of Health and Human services, a US-based government agency, the use of assisted reproductive technology (ART) increases with maternal age. In 2023, 9% of live births among women aged 40-45 involved ART, rising to nearly one-third for women 45 and older. ART usage also varies by region in the U.S. Therefore, the increasing adoption of assisted reproductive technology is driving the follicle-stimulating hormone market.

Key Players In The Global Follicle Stimulating Hormone Market

Major companies operating in the follicle stimulating hormone market are Pfizer Inc., Sanofi S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Cipla Ltd., Ferring Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Emcure Pharmaceuticals Ltd., IBSA Group, Taj Pharmaceuticals Ltd., Trumac Healthcare, Midas Pharma GmbH, Shanghai Techwell Biopharmaceutical Co. Ltd., Livzon Pharmaceutical Group Inc., Anhui Anke Biotechnology Group Co. Ltd., LG Chem Life Sciences, Genpharm Inc., Biogenix Inc. Pvt. Ltd.

Global Follicle Stimulating Hormone Market Trends and Insights

Major companies operating in the follicle-stimulating hormone market are developing innovative products such as multi-hormone at-home diagnostic testing systems to provide more accurate, continuous, and patient-centric insights into hormone health and reproductive function. Multi-hormone at-home diagnostic testing systems refer to integrated, user-friendly platforms that measure FSH alongside other key reproductive hormones through non-invasive sampling, enabling real-time monitoring, personalized health assessments, and improved clinical decision-making without requiring in-clinic testing. For instance, in July 2024, Proov, a US-based women's health company, launched the Proov Empower Perimenopause Testing System. Proov Empower offers comprehensive and personalized insights into how a woman’s changing hormones affect her overall health and wellness. This non-invasive, multi-time point urine test measures four key hormones FSH, estrogen marker E1G, progesterone marker PdG, and LH that influence symptoms and the perimenopause experience. By providing periodic retesting, Proov Empower helps women track hormone fluctuations and symptoms, serving as a valuable guide during the transition to menopause.

What Are Latest Mergers And Acquisitions In The Follicle Stimulating Hormone Market?

In September 2024, Organon China, a China-based healthcare company, partnered with Shanghai Bao Pharmaceutical for SJ02, a Long-Acting FSH in the BLA Process, an Innovative Investigational Asset in Assisted Reproductive Technology (ART) in China Mainland. As a result of this partnership, Organon is advancing its 'In China, for China' strategy and expanding its fertility portfolio. By collaborating with China’s leading innovators, Organon aims to accelerate progress in assisted reproductive technology (ART) and provide additional fertility options to millions of Chinese families. Shanghai Bao Pharmaceutical is a China-based provider of follicle-stimulating hormone (FSH).

Regional Insights

North America was the largest region in the follicle stimulating hormone market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Follicle Stimulating Hormone Market?

The follicle-stimulating hormone market consists of sales of luteinizing hormone (LH), chorionic gonadotropin (CG), and thyroid-stimulating hormone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Follicle Stimulating Hormone Market Report 2026?

The follicle stimulating hormone market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the follicle stimulating hormone industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.